Publications by authors named "R Andtbacka"
Article Synopsis
- Scientists believe that delivering special medicines directly into tumors could help fight cancer better.
- An expert group worked together to figure out how to create better tests for these new treatments, including which patients to help.
- They discussed different ideas on how to design these tests, so they can learn the most about how well the new therapies work for different types of cancer.
Article Synopsis
- Mavorixafor is a new oral drug targeting the CXCR4 receptor, aimed at improving immune cell activity in melanoma patients, tested in a small study alongside the existing treatment pembrolizumab.
- The study found that mavorixafor increased CD8 T-cell presence and other markers of immune activation in tumor samples, suggesting it could enhance immune responses in tumors.
- Safety assessments indicated manageable side effects, supporting the idea that mavorixafor could be a promising option for patients not responding to current treatments.
Background: Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell death 1 (PD-1) antibody pembrolizumab. We report results from an open-label, single-arm, phase 1b study (NCT02307149) evaluating V937 plus the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab in patients with advanced melanoma.
Methods: Adult patients (aged ≥18 years) with histologically confirmed metastatic or unresectable stage IIIB/C or IV melanoma received intratumoral V937 on days 1, 3, 5, 8, and 22 and every 3 weeks (Q3W) thereafter for up to 19 sets of injections plus intravenous ipilimumab 3 mg/kg Q3W administered for four doses starting on day 22.
Article Synopsis
- The study investigated how different types of NADPH oxidases (NOX1, NOX2, and NOX4) contribute to vascular dysfunction related to ageing in human skeletal muscle feed arteries.
- Researchers compared vasodilation responses in young, middle-aged, and older subjects under conditions with and without specific inhibitors for each NOX isoform.
- The findings showed that while NOX1 had no impact, inhibiting NOX2 improved vascular responses in older and middle-aged groups, suggesting that NOX2 and NOX4 are key players in age-related endothelial dysfunction, likely through nitric oxide mechanisms.